Pierluigi Tricoci Selected Research

human APOA1 protein

1/2019	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
5/2018	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierluigi Tricoci Research Topics

Disease

56	Acute Coronary Syndrome 01/2022 - 09/2002
39	Myocardial Infarction 01/2022 - 10/2005
31	Hemorrhage 01/2020 - 09/2002
18	Stroke (Strokes) 12/2018 - 04/2006
8	Ischemia 03/2017 - 02/2011
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 03/2007
4	ST Elevation Myocardial Infarction 01/2017 - 05/2007
4	Unstable Angina 01/2017 - 04/2006
4	Thrombosis (Thrombus) 05/2016 - 05/2007
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2016
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2021
2	Peripheral Arterial Disease 01/2021 - 10/2014
2	Acute Kidney Injury (Acute Renal Failure) 01/2019 - 08/2016
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 12/2018 - 01/2012
2	Atherosclerosis 05/2018 - 08/2015
2	Atrial Fibrillation 05/2017 - 10/2013
2	Transient Ischemic Attack 05/2017 - 06/2015
1	Body Weight (Weight, Body) 01/2021
1	Chronic Renal Insufficiency 01/2019
1	Hemorrhagic Stroke 12/2018
1	Injection Site Reaction 11/2018
1	Gout 05/2017
1	Peptic Ulcer (Peptic Ulcers) 01/2017
1	Non-ST Elevated Myocardial Infarction 01/2017
1	Albuminuria 08/2016
1	Diabetes Mellitus 03/2014
1	Death (Near-Death Experience) 10/2013
1	Infarction (Infarctions) 06/2013
1	Renal Insufficiency (Renal Failure) 11/2011
1	Coronary Disease (Coronary Heart Disease) 07/2009
1	Inflammation (Inflammations) 03/2007
1	Hypercholesterolemia 04/2006

Drug/Important Bio-Agent (IBA)

22	vorapaxarIBA 12/2018 - 10/2010
20	Thrombin Receptors (Thrombin Receptor)IBA 01/2020 - 10/2010
11	Glycoproteins (Glycoprotein)IBA 01/2018 - 10/2006
8	CSL112IBA 01/2022 - 08/2015
8	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 08/2015
7	Clopidogrel (Plavix)FDA Link 01/2015 - 10/2005
7	Eptifibatide (Integrilin)FDA Link 10/2013 - 05/2007
6	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017 - 04/2006
5	CholesterolIBA 01/2022 - 10/2016
5	alirocumabIBA 01/2019 - 11/2014
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 11/2014
5	Peptide Hydrolases (Proteases)FDA Link 12/2018 - 01/2012
4	CreatinineIBA 01/2019 - 11/2011
4	Platelet Membrane Glycoprotein IIbIBA 05/2015 - 05/2007
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2013
3	oxidized low density lipoproteinIBA 01/2019 - 11/2014
3	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 05/2018 - 10/2013
3	PAR-1 ReceptorIBA 12/2015 - 07/2014
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 12/2015 - 10/2010
3	TroponinIBA 06/2015 - 07/2013
3	Enoxaparin (Lovenox)FDA LinkGeneric 07/2013 - 09/2002
2	apixabanIBA 01/2020 - 01/2016
2	human APOA1 proteinIBA 01/2019 - 05/2018
2	Monoclonal AntibodiesIBA 11/2018 - 11/2014
2	LDL CholesterolIBA 11/2018 - 11/2014
2	HDL LipoproteinsIBA 10/2016 - 08/2015
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 06/2015 - 09/2002
2	Pharmaceutical PreparationsIBA 09/2014 - 11/2011
1	MDCO-216IBA 01/2022
1	CER-001IBA 01/2022
1	ApoproteinsIBA 01/2022
1	LipidsIBA 01/2022
1	Lipoproteins (Lipoprotein)IBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	HDL CholesterolIBA 11/2018
1	LDL Lipoproteins (beta Lipoproteins)IBA 11/2018
1	Proprotein Convertase 9IBA 11/2018
1	ApolipoproteinsIBA 11/2018
1	protease-activated receptor 4IBA 01/2018
1	Uric Acid (Urate)IBA 05/2017
1	thienopyridineIBA 03/2017
1	omega-Chloroacetophenone (Mace)IBA 08/2016
1	Thrombin FDA Link 01/2015
1	TicagrelorIBA 01/2015
1	AnticoagulantsIBA 01/2015
1	Prasugrel Hydrochloride FDA Link 01/2015
1	MetalsIBA 09/2014
1	cangrelorIBA 09/2013
1	trans-crotonin (CTN)IBA 07/2013
1	Proteinase-Activated ReceptorsIBA 06/2013
1	MB Form Creatine KinaseIBA 12/2012
1	E 5555IBA 10/2010
1	Adenosine Diphosphate (ADP)IBA 07/2009
1	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2007
1	Streptokinase FDA Link 12/2007
1	Matrix Metalloproteinases (MMPs)IBA 03/2007

Therapy/Procedure

20	Therapeutics 01/2022 - 10/2005
17	Percutaneous Coronary Intervention 01/2020 - 10/2006
8	Patient Readmission 03/2017 - 01/2012
7	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 04/2006
4	Stents 05/2016 - 07/2009
2	Drug Therapy (Chemotherapy) 01/2021 - 10/2016
1	Secondary Prevention 12/2018
1	Injections 11/2014
1	Drug-Eluting Stents 09/2014
1	Dual Anti-Platelet Therapy 06/2013
1	Blood Transfusion (Blood Transfusions) 12/2007
1	Time-to-Treatment 09/2002